(Q24236620)

3

0 references

Francesca Sperati

5

0 references

Irene Terrenato

4

0 references

Elie A Akl

1

0 references

Nawman Labedi

2

object named as

Nawman Labedi

0 references

Paola Muti

Cochrane Database of Systematic Reviews

6

object named as

Paola Muti

0 references

publication date

15 June 2011

0 references

published in

0 references

cites work

Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006650.PUB3

Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006650.PUB3

Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006650.PUB3

Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006650.PUB3

Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006650.PUB3

Long-term use of different doses of low-molecular-weight heparin versus vitamin K antagonists in the treatment of venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006650.PUB3

Secondary Prevention of Venous Thromboembolism with the Oral Direct Thrombin Inhibitor Ximelagatran

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006650.PUB3

Dabigatran versus warfarin in the treatment of acute venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006650.PUB3

Blood and neoplastic diseases. Thrombosis: treatment and prophylaxis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006650.PUB3

Low-molecular-weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006650.PUB3

Long-term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006650.PUB3

Does low-molecular-weight heparin influence cancer-related mortality?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006650.PUB3

Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006650.PUB3

Venographic comparison of subcutaneous low-molecular weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006650.PUB3

Long-term anticoagulation prophylaxis following acute thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006650.PUB3

Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006650.PUB3

Extended enoxaparin monotherapy for acute symptomatic pulmonary embolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006650.PUB3

From Trousseau to targeted therapy: new insights and innovations in thrombosis and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006650.PUB3

An open-label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006650.PUB3

Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006650.PUB3

Long-term therapy of venous thromboembolism in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006650.PUB3

Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006650.PUB3

Low-molecular-weight heparin and cancer survival: review of the literature and pooled analysis of 1,726 patients treated for at least three months

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006650.PUB3

Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006650.PUB3

Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006650.PUB3

Deep vein thrombosis of the leg. Is there a "high risk" group?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006650.PUB3

Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006650.PUB3

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006650.PUB3

Prognosis of Cancers Associated with Venous Thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006650.PUB3

Anticoagulation therapy for venous thromboembolism in patients with gynecologic malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006650.PUB3

7 January 2021

Diagnosis and treatment of recurrent venous thromboembolism

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006650.PUB3

7 January 2021

Incidence of cancer after a first episode of idiopathic venous thromboembolism treated with 3 months or 1 year of oral anticoagulation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006650.PUB3

7 January 2021

Lack of effect of coumarin in women with lymphedema after treatment for breast cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006650.PUB3

7 January 2021

Anti-Xa effect of a low molecular weight heparin (dalteparin) does not accumulate in extended duration therapy for venous thromboembolism in cancer patients.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006650.PUB3

7 January 2021

Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006650.PUB3

7 January 2021

Treatment of venous thromboembolism in cancer patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006650.PUB3

7 January 2021